biotech investing BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer
biotech investing BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+
biotech investing BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+ for Prostate Cancer
biotech investing BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
biotech investing BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
biotech investing BriaCell Receives FDA Clearance to Initiate Bria-BRES+ Clinical Study in Breast Cancer
biotech investing BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+ in Preclinical Cancer Models
biotech investing BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
biotech investing BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
Steadright Removes Titanbeach One Technical Report And Retains Qualified Geologist For New Technical Report
The Metal You've Never Heard Of Is Becoming a National-Security Priority -- and America Barely Mines It
